Landmark TIOSPIRTM trial reinforces importance of SPIRIVA ® in both available formulations as the world ' s leading maintenance therapy for chronic obstructive pulmonary disease (COPD)

Landmark TIOSPIRTM trial reinforces importance of SPIRIVA ® in both available formulations as the world ' s leading maintenance therapy for chronic obstructive pulmonary disease (COPD)
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news